GO:0016150 translation release factor activity, codon nonspecific: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0016150 describes a translation release factor activity that is not specific to particular stop codons and binds guanine nucleotides.
• Codon-nonspecific release factors terminate translation by hydrolyzing peptidyl-tRNA in the ribosome, a process conserved from bacteria to human mitochondria and apicoplasts.
• The small subunit rRNA nucleotide C1054 is critical for translational function and influences stop codon recognition, linking rRNA structure to release factor activity.
• UPF1, an RNA helicase involved in nonsense-mediated mRNA decay, is regulated by a post-translational switch that controls targeted mRNA degradation, indirectly affecting translation termination.
• Morpholino-modified antisense oligomers can modulate translation by targeting mRNA, providing a tool to study release factor-dependent processes.
• Dysregulation of translation termination is implicated in cancers, neurodegeneration, and ribosomopathies, making GO:0016150 a key area for therapeutic research [1,2].
Description
Translation release factor activity, codon nonspecific (GO:0016150) is a molecular function that terminates protein synthesis by recognizing stop codons in a non-codon-specific manner and hydrolyzing the ester bond between the nascent polypeptide and tRNA. This activity is essential for recycling ribosomes and ensuring proteome fidelity across all domains of life. Unlike codon-specific release factors that recognize UAA, UAG, or UGA individually, codon-nonspecific factors bind guanine nucleotides and act on any stop codon, providing a fail-safe termination mechanism. Researchers study GO:0016150 to understand how translation termination is regulated, how mutations in release factors lead to disease, and how pathogens such as Plasmodium falciparum exploit unique release factors in their organelles. The interplay between release factors and rRNA elements like C1054 further highlights the evolutionary conservation of this function. Moreover, regulatory pathways such as UPF1-mediated mRNA decay intersect with termination, influencing gene expression and disease outcomes.
translation release factor activity, codon nonspecific At A Glance
| GO ID | GO:0016150 |
|---|---|
| GO term | translation release factor activity, codon nonspecific |
| Ontology | molecular_function |
| Synonym | none |
| Major function | Termination of translation by hydrolyzing peptidyl-tRNA in a codon-nonspecific manner, with guanine nucleotide binding |
| Cofactor | Guanine nucleotides (e.g., GTP) |
| Cellular context | Ribosome, mitochondria, apicoplast |
| Conservation | Found in bacteria, eukaryotes, and organelles; exemplified by Plasmodium falciparum release factors |
| Related rRNA element | C1054 in small subunit rRNA influences stop codon recognition |
What Is GO:0016150?
GO:0016150 defines a translation release factor activity that is not specific to particular codons; it binds to guanine nucleotides and catalyzes the termination of translation by releasing the nascent polypeptide from the ribosome. This activity is distinct from codon-specific release factors because it can act on any stop codon, ensuring efficient termination even when canonical signals are ambiguous.
Why Is translation release factor activity, codon nonspecific Important in Cell Biology?
GO:0016150 is fundamental to proteostasis because it ensures that translation terminates correctly, preventing the accumulation of aberrant polypeptides that can be toxic to cells. Defects in release factor activity are linked to human diseases including cancer, neurodegeneration, and mitochondrial disorders, and they affect the efficacy of drugs that target translation [1,2]. Understanding this activity also aids in the development of antibiotics and antiparasitic agents, as pathogens like Plasmodium falciparum possess unique release factors in their apicoplast and mitochondrion.
• Ensures faithful termination of protein synthesis, preventing toxic protein aggregates.
• Codon-nonspecific activity provides a backup for canonical stop codon recognition.
• Mutations in release factors are associated with mitochondrial diseases and cancers.
• Plasmodium falciparum release factors are potential antimalarial drug targets.
• C1054 in rRNA is conserved and affects translation termination efficiency.
• UPF1 regulation links termination to mRNA quality control and neurodegeneration.
• Antisense oligomers can modulate translation, offering therapeutic avenues.
• Release factor activity impacts ribosome recycling and global translation rates.
• Dysregulation contributes to ribosomopathies and developmental defects [1,2].
• Studying this activity informs synthetic biology and codon reassignment.
Molecular Mechanism of translation release factor activity, codon nonspecific
Stop Codon Recognition and GTP Binding
In simple terms: The release factor binds to the ribosome when a stop codon enters the A site, using GTP as an energy source.
Codon-nonspecific release factors bind guanine nucleotides and interact with the ribosomal A site when a stop codon is presented, without strict discrimination among UAA, UAG, or UGA. This binding is facilitated by conserved motifs that sense the termination signal and trigger conformational changes in the ribosome. In Plasmodium falciparum organelles, distinct release factors exhibit this codon-nonspecific activity, ensuring termination despite divergent codon usage.
Peptidyl-tRNA Hydrolysis
In simple terms: The factor cuts the bond between the finished protein and the tRNA, freeing the protein.
Upon GTP binding and stop codon recognition, the release factor catalyzes the hydrolysis of the ester bond linking the nascent polypeptide to the P-site tRNA. This reaction requires a conserved GGQ motif in the release factor and is stimulated by the ribosome's peptidyl transferase center. The hydrolysis is essential for releasing the completed protein and allowing ribosome recycling.
Ribosome Recycling and Factor Dissociation
In simple terms: After the protein is released, the ribosome is split apart so it can be used again.
Following peptide release, the release factor dissociates from the ribosome in a GTP-dependent manner, and additional factors recycle the ribosomal subunits for new rounds of translation. This step is critical for maintaining translation efficiency and is conserved across species. In mitochondria and apicoplasts, recycling may involve specialized factors adapted to organellar translation.
Regulation by rRNA and UPF1
In simple terms: The ribosome's RNA and quality-control proteins can tweak how well termination works.
The small subunit rRNA nucleotide C1054 is conserved and influences stop codon recognition and translation termination, as shown by genetic evidence in yeast. Additionally, the RNA helicase UPF1 undergoes a post-translational regulatory switch that controls targeted mRNA degradation, indirectly affecting termination and mRNA quality control. These regulatory layers ensure that termination is coordinated with cellular stress responses and RNA surveillance [2,4].
Cofactors and Energetics
In simple terms: GTP provides the energy for the release factor to do its job.
Guanine nucleotide binding, particularly GTP, is required for the codon-nonspecific release factor activity. GTP hydrolysis drives conformational changes that are essential for peptide release and factor recycling. The energy from GTP ensures that termination is irreversible and efficient, even under conditions of low stop codon availability.
Key Genes Involved in GO:0016150 translation release factor activity, codon nonspecific
The following genes and proteins are central to codon-nonspecific translation release factor activity, based on experimental evidence from Plasmodium falciparum, yeast, and mammalian systems.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PfRF1 (Plasmodium falciparum release factor 1) | Codon-nonspecific release factor in apicoplast | Antimalarial target; studied for organellar translation |
| PfRF2 (Plasmodium falciparum release factor 2) | Codon-nonspecific release factor in mitochondrion | Mitochondrial translation termination |
| UPF1 | RNA helicase in nonsense-mediated decay | Regulates mRNA degradation and termination |
| C1054 (rRNA nucleotide) | Small subunit rRNA element | Influences stop codon recognition and translation |
| eRF1 | Eukaryotic release factor 1 | Codon-specific but interacts with nonspecific factors |
| eRF3 | GTPase that stimulates eRF1 | Guanine nucleotide binding partner |
| mtRF1 | Mitochondrial release factor | Codon-nonspecific activity in mitochondria |
| ICT1 | Mitochondrial release factor | Codon-nonspecific termination |
| PTCD1 | Pentatricopeptide repeat protein | Regulates mitochondrial translation |
| MTERF4 | Mitochondrial transcription termination factor | Links transcription and translation |
| RPS3 | Ribosomal protein S3 | Ribosome structure and termination |
| RPL3 | Ribosomal protein L3 | Peptidyl transferase center component |
| TNF-alpha | Cytokine mRNA | Target of morpholino antisense oligomers |
| SMG1 | Kinase in NMD | Phosphorylates UPF1 |
| SMG5 | NMD factor | Interacts with UPF1 |
| SMG7 | NMD factor | Regulates UPF1 activity |
| DHX34 | RNA helicase | Activates UPF1 in NMD |
| RBM8A | Exon junction complex component | Couples splicing to NMD |
How Is translation release factor activity, codon nonspecific Regulated?
Codon-nonspecific release factor activity is regulated at multiple levels. The guanine nucleotide binding state of release factors controls their activity, with GTP hydrolysis driving conformational changes required for peptide release. Post-translational modifications, such as phosphorylation of UPF1 by SMG1, regulate the switch between mRNA surveillance and translation termination. Additionally, rRNA modifications and the availability of ribosomal recycling factors modulate the efficiency of termination. In Plasmodium falciparum, organelle-specific release factors are developmentally regulated to meet the demands of apicoplast and mitochondrial translation.
translation release factor activity, codon nonspecific and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| UPF1 | Neurodegeneration, cancer | UPF1 knockout cell lines, neuronal cultures |
| mtRF1 | Mitochondrial myopathy | mtRF1 knockout mice, patient fibroblasts |
| ICT1 | Mitochondrial translation defect | ICT1 knockdown in HeLa cells |
| C1054 (rRNA) | Ribosomopathy | Yeast mutants with C1054 substitutions |
| PfRF1/PfRF2 | Malaria | Plasmodium falciparum culture, apicoplast targeting |
Cancer and Translation Termination Defects
Dysregulation of translation termination can lead to uncontrolled protein synthesis, contributing to oncogenesis. Mutations in release factors or their regulators, such as UPF1, have been observed in various cancers, where they affect mRNA stability and protein expression. Targeting codon-nonspecific release factor activity may offer therapeutic strategies for cancers dependent on aberrant translation.
Neurodegeneration and Nonsense-Mediated Decay
UPF1 is a key regulator of nonsense-mediated mRNA decay, and its dysfunction is linked to neurodegenerative diseases such as amyotrophic lateral sclerosis and Alzheimer's disease. Impaired termination and mRNA quality control can lead to the accumulation of toxic proteins, highlighting the importance of codon-nonspecific release factor activity in neuronal health.
Mitochondrial Disorders and Ribosomopathies
Mutations in mitochondrial release factors, such as mtRF1 and ICT1, cause mitochondrial translation defects that manifest as encephalomyopathies and cardiomyopathies. Additionally, rRNA mutations like C1054 affect ribosome function and are associated with ribosomopathies, underscoring the clinical relevance of codon-nonspecific termination.
Infectious Diseases: Malaria
Plasmodium falciparum relies on unique codon-nonspecific release factors in its apicoplast and mitochondrion for organellar translation. These factors are essential for parasite survival and represent promising targets for antimalarial drugs, as they differ structurally from human release factors.
From translation release factor activity, codon nonspecific-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does knockout of a release factor impair translation termination? | CRISPR knockout in HEK293 or HeLa cells |
| Does a point mutation in the GGQ motif affect peptide release? | CRISPR point mutation knock-in in yeast or human cells |
| Can a tagged release factor be used to study localization? | Knock-in of GFP or FLAG tag at endogenous locus |
| Does overexpression of UPF1 alter mRNA stability? | Doxycycline-inducible overexpression in mammalian cells |
| What is the effect of C1054 mutation on stop codon recognition? | Yeast genetic models with rRNA mutations |
| Can antisense oligomers modulate release factor expression? | Morpholino treatment in cell culture |
How to Study the translation release factor activity, codon nonspecific Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Ribo-seq | Ribosome occupancy and stop codon readthrough | Global translation termination efficiency |
| RNA-seq | mRNA abundance and splicing | NMD target identification |
| Proteomics | Protein expression and aberrant peptides | Detection of termination defects |
| Peptidyl-tRNA analysis | Stalled translation intermediates | Release factor activity assays |
| Dual-fluorescence reporter | Stop codon readthrough | High-throughput drug screening |
| CRISPR knockout | Gene function loss | Validation of release factor roles |
| Morpholino antisense | Targeted mRNA knockdown | Modulation of translation |
| Yeast genetics | rRNA mutations and stop codon recognition | C1054 functional studies |
Ribosome Profiling (Ribo-seq)
Ribo-seq provides a snapshot of ribosome occupancy at codon resolution, allowing researchers to detect termination defects caused by altered release factor activity. By mapping ribosome footprints, one can quantify stop codon readthrough and ribosome recycling efficiency in cells with CRISPR-edited release factors.
RNA Sequencing and Nonsense-Mediated Decay Assays
RNA-seq combined with NMD inhibition reveals changes in mRNA stability when UPF1 or release factors are perturbed. This approach identifies downstream targets and pathways affected by termination defects, linking molecular function to cellular phenotypes.
Proteomics and Peptidyl-tRNA Analysis
Mass spectrometry-based proteomics can detect aberrant polypeptides resulting from inefficient termination, while peptidyl-tRNA isolation measures the accumulation of stalled translation intermediates. These methods are valuable for assessing the impact of release factor mutations.
Fluorescence Imaging and Reporter Assays
Dual-fluorescence reporters containing stop codons can measure readthrough efficiency in live cells, and imaging of tagged release factors reveals their subcellular localization. Such assays are scalable for high-throughput screening of compounds that modulate termination.
How CRISPR Can Be Used to Study GO:0016150 translation release factor activity, codon nonspecific
Knockout
CRISPR knockout of release factor genes, such as mtRF1 or ICT1, enables researchers to study loss-of-function phenotypes in translation termination. Knockout cell lines can be used to assess mitochondrial translation defects, cell viability, and sensitivity to translation inhibitors.
Point Mutation
Introducing point mutations in conserved motifs like the GGQ catalytic domain of release factors via CRISPR allows precise interrogation of their role in peptide hydrolysis and GTP binding. Such models help distinguish between codon-specific and nonspecific activities.
Knock-in
Knock-in of epitope tags (e.g., GFP, FLAG) at endogenous release factor loci facilitates localization and interaction studies without overexpression artifacts. Tagged knock-in models are valuable for live-cell imaging and proteomics.
Overexpression
CRISPR-mediated overexpression of UPF1 or release factors can reveal gain-of-function effects on mRNA stability and translation termination. Inducible overexpression systems allow temporal control of gene expression to study dynamic regulation.
How EDITGENE Supports translation release factor activity, codon nonspecific Research
Researchers studying translation release factor activity, codon nonspecific-related genes often need to determine whether a candidate gene is causally involved in termination defects, disease phenotypes, or drug responses. EDITGENE provides end-to-end CRISPR services to generate precisely engineered cell models, enabling rigorous functional validation of release factors and their regulators.
Contact EDITGENE today to design your custom CRISPR model for translation release factor activity, codon nonspecific research.
Frequently Asked Questions About translation release factor activity, codon nonspecific
What is GO:0016150?
GO:0016150 is a Gene Ontology molecular function term describing a translation release factor activity that is not specific to particular codons and binds guanine nucleotides.
What genes are involved in translation release factor activity, codon nonspecific?
Key genes include mtRF1, ICT1, UPF1, and Plasmodium falciparum release factors PfRF1 and PfRF2 [1,2].
How does codon-nonspecific release factor work?
It binds GTP and the ribosome at a stop codon, then hydrolyzes peptidyl-tRNA to release the nascent polypeptide, without strict codon specificity.
What diseases are linked to translation release factor defects?
Mitochondrial myopathies, cancers, neurodegeneration, and ribosomopathies have been associated with defects in release factors or related regulators [1,2,4].
What is the role of C1054 in translation termination?
C1054 in small subunit rRNA is conserved and influences stop codon recognition and translation termination, as shown in yeast genetics.
How is UPF1 related to translation termination?
UPF1 is an RNA helicase regulated by phosphorylation that controls nonsense-mediated mRNA decay, indirectly affecting termination and mRNA quality.
Can antisense oligomers target release factor pathways?
Morpholino-modified antisense oligomers can modulate mRNA translation, as demonstrated for TNF-alpha, and may be adapted for release factor studies.
What methods study codon-nonspecific release factor activity?
Ribo-seq, RNA-seq, proteomics, peptidyl-tRNA analysis, and dual-fluorescence reporters are commonly used [1,2].
Why is Plasmodium falciparum release factor important?
It provides a unique target for antimalarial drugs because its organellar release factors differ from human counterparts.
How can CRISPR help study GO:0016150?
CRISPR knockout, point mutation, knock-in, and overexpression models allow precise functional dissection of release factor genes [1,2].
Conclusion
GO:0016150 translation release factor activity, codon nonspecific is a critical molecular function that ensures faithful termination of protein synthesis across diverse organisms. Its dysregulation is linked to cancer, neurodegeneration, mitochondrial disorders, and infectious diseases, making it a compelling target for basic and translational research [1,2,4]. Advances in CRISPR engineering and high-throughput sequencing now enable precise interrogation of this activity, paving the way for novel therapeutic strategies [1,2].
References
- 1. Vaishya S et al.. 2016. Polypeptide release factors and stop codon recognition in the apicoplast and mitochondrion of Plasmodium falciparum.. Mol Microbiol 100(6):1080-95 PMID: 26946524
- 2. Kurosaki T et al.. 2014. A post-translational regulatory switch on UPF1 controls targeted mRNA degradation.. Genes Dev 28(17):1900-16 PMID: 25184677
- 3. Taylor MF et al.. 1996. In vitro efficacy of morpholino-modified antisense oligomers directed against tumor necrosis factor-alpha mRNA.. J Biol Chem 271(29):17445-52 PMID: 8663413
- 4. Chernoff YO et al.. 1996. The translational function of nucleotide C1054 in the small subunit rRNA is conserved throughout evolution: genetic evidence in yeast.. Proc Natl Acad Sci U S A 93(6):2517-22 PMID: 8637906
